AssetMark Inc’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.9M | Buy |
61,463
+9,076
| +17% | +$1.62M | 0.02% | 470 |
|
|
2026
Q1 | $9.04M | Buy |
52,387
+8,578
| +20% | +$1.59M | 0.02% | 529 |
|
|
2025
Q4 | $8.74M | Buy |
43,809
+6,666
| +18% | +$1.21M | 0.02% | 524 |
|
|
2025
Q3 | $5.81M | Buy |
37,143
+6,301
| +20% | +$1M | 0.01% | 591 |
|
|
2025
Q2 | $4.68M | Buy |
30,842
+18,557
| +151% | +$2.47M | 0.01% | 599 |
|
|
2025
Q1 | $1.85M | Buy |
12,285
+2,510
| +26% | +$421K | 0.01% | 743 |
|
|
2024
Q4 | $1.8M | Buy |
9,775
+9,587
| +5,099% | +$1.85M | ﹤0.01% | 734 |
|
|
2024
Q3 | $37K | Buy |
188
+173
| +1,153% | +$36K | ﹤0.01% | 1363 |
|
|
2024
Q2 | $3.1K | Buy |
15
+9
| +150% | +$2.04K | ﹤0.01% | 1675 |
|
|
2024
Q1 | $1.63K | Buy |
+6
| New | +$1.43K | ﹤0.01% | 1610 |
|
|
2023
Q4 | – | Sell |
-13
| Closed | -$2.55K | – | 1861 |
|
|
2023
Q3 | $2.55K | Hold |
13
| – | – | ﹤0.01% | 1451 |
|
|
2023
Q2 | $2.73K | Hold |
13
| – | – | ﹤0.01% | 1394 |
|
|
2023
Q1 | $2.62K | Sell |
13
-3
| -19% | -$680 | ﹤0.01% | 1374 |
|
|
2022
Q4 | $3.49K | Hold |
16
| – | – | ﹤0.01% | 1389 |
|
|
2022
Q3 | $3K | Hold |
16
| – | – | ﹤0.01% | 1350 |
|
|
2022
Q2 | $3K | Hold |
16
| – | – | ﹤0.01% | 1339 |
|
|
2022
Q1 | $5K | Sell |
16
-66
| -80% | -$20.4K | ﹤0.01% | 1267 |
|
|
2021
Q4 | $31K | Buy |
82
+15
| +22% | +$5.83K | ﹤0.01% | 998 |
|
|
2021
Q3 | $28K | Hold |
67
| – | – | ﹤0.01% | 883 |
|
|
2021
Q2 | $25K | Buy |
67
+58
| +644% | +$19.4K | ﹤0.01% | 867 |
|
|
2021
Q1 | $3K | Sell |
9
-347
| -97% | -$96.5K | ﹤0.01% | 1097 |
|
|
2020
Q4 | $89K | Buy |
356
+173
| +95% | +$41.2K | ﹤0.01% | 626 |
|
|
2020
Q3 | $41K | Buy |
183
+127
| +227% | +$26.4K | ﹤0.01% | 710 |
|
|
2020
Q2 | $10K | Sell |
56
-226
| -80% | -$36.1K | ﹤0.01% | 862 |
|
|
2020
Q1 | $36K | Buy |
282
+158
| +127% | +$23.7K | ﹤0.01% | 753 |
|
|
2019
Q4 | $19K | Buy |
124
+121
| +4,033% | +$16.8K | ﹤0.01% | 935 |
|
|
2019
Q3 | $0 | Sell |
3
-7
| -70% | -$939 | ﹤0.01% | 1323 |
|
|
2019
Q2 | $1K | Buy |
+10
| New | +$1.36K | ﹤0.01% | 1221 |
|
|
2019
Q1 | – | Sell |
-4
| Closed | – | – | 1372 |
|
|
2018
Q4 | $0 | Buy |
+4
| New | +$501 | ﹤0.01% | 1447 |
|
|
2016
Q1 | – | Sell |
-7
| Closed | -$1K | – | 1211 |
|
|
2015
Q4 | $1K | Buy |
+7
| New | +$505 | ﹤0.01% | 1187 |
|
Other funds holding CRL
AI
AssetMark Inc's CRL Position: Q2 2026 in Review
AssetMark Inc increased its Charles River Laboratories (CRL) stake by 17% in Q2 2026, buying an estimated $1.62M and bringing the position to 61,463 shares worth $13.9M. The position accounts for 0.02% of the portfolio, ranked #470.
AssetMark Inc first reported a position in CRL in Q4 2015 and has held it in 30 quarters since. 569 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- AssetMark Inc held 61,463 shares of Charles River Laboratories worth $13.9M as of Q2 2026.
- AssetMark Inc bought 9,076 Charles River Laboratories shares in Q2 2026, an estimated $1.62M.
- Charles River Laboratories made up 0.02% of AssetMark Inc's portfolio in Q2 2026, its #470 holding.
- AssetMark Inc first reported a position in Charles River Laboratories in Q4 2015 and has held it in 30 quarters since.
- 569 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.